Loading…

Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents

A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exe...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2017-05, Vol.132, p.173-183
Main Authors: Chen, Jichao, Wang, Tianyu, Xu, Shengtao, Lin, Aijun, Yao, Hequan, Xie, Weijia, Zhu, Zheying, Xu, Jinyi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3
cites cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3
container_end_page 183
container_issue
container_start_page 173
container_title European journal of medicinal chemistry
container_volume 132
creator Chen, Jichao
Wang, Tianyu
Xu, Shengtao
Lin, Aijun
Yao, Hequan
Xie, Weijia
Zhu, Zheying
Xu, Jinyi
description A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents. [Display omitted] •Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.
doi_str_mv 10.1016/j.ejmech.2017.03.027
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1883177323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417301848</els_id><sourcerecordid>1883177323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpSLZp_kEpOvZQu_qyZF8KJU3aQiCX9Cy00nijxZZSSTbZfx8tm_ZYGJiBeeedmQehD5S0lFD5Zd_Cfgb72DJCVUt4S5h6gzZUyb7hrBNv0YYwxpuOcXGB3uW8J4R0kpBzdMF63g1EdBt0-A7Z78JnnA-hPNY6YxMc3vo4xZ23ZsKwmmkxxceA44hDXGHCwZfkLY7P3kHjYqjtsMNPKZa4hVTDB8CuprV2VqieR9viyzLHhM0OQsnv0dlopgxXr_kS_b69ebj-2dzd__h1_e2usVyy0ijFpJOdM0IxYpUCkE5IIYFtpRnNIBlTYmDDyIEyy6QYhTOS9sYSyQdj-CX6dPKt5_1ZIBc9-2xhmkyAuGRN-55TpTjjVSpOUptizglG_ZT8bNJBU6KP0PVen6DrI3RNuK7Q69jH1w3Ldgb3b-gv5Sr4ehJA_XP1kHS2HoIF5xPYol30_9_wAuUulz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883177323</pqid></control><display><type>article</type><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><source>Elsevier</source><creator>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</creator><creatorcontrib>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</creatorcontrib><description>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents. [Display omitted] •Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.03.027</identifier><identifier>PMID: 28359045</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antitumor activity ; Apoptosis - drug effects ; Berberine ; Berberine Alkaloids - chemistry ; Berberine Alkaloids - pharmacology ; Carcinoma, Hepatocellular - drug therapy ; Cell Cycle Checkpoints - drug effects ; Hep G2 Cells ; Heterografts ; Humans ; Hybrid compound ; Liver Neoplasms - drug therapy ; Mice ; Nitric oxide (NO) donor ; Nitric Oxide - metabolism ; Palmatine</subject><ispartof>European journal of medicinal chemistry, 2017-05, Vol.132, p.173-183</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</citedby><cites>FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28359045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jichao</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Xu, Shengtao</creatorcontrib><creatorcontrib>Lin, Aijun</creatorcontrib><creatorcontrib>Yao, Hequan</creatorcontrib><creatorcontrib>Xie, Weijia</creatorcontrib><creatorcontrib>Zhu, Zheying</creatorcontrib><creatorcontrib>Xu, Jinyi</creatorcontrib><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents. [Display omitted] •Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antitumor activity</subject><subject>Apoptosis - drug effects</subject><subject>Berberine</subject><subject>Berberine Alkaloids - chemistry</subject><subject>Berberine Alkaloids - pharmacology</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Cell Cycle Checkpoints - drug effects</subject><subject>Hep G2 Cells</subject><subject>Heterografts</subject><subject>Humans</subject><subject>Hybrid compound</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Mice</subject><subject>Nitric oxide (NO) donor</subject><subject>Nitric Oxide - metabolism</subject><subject>Palmatine</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpSLZp_kEpOvZQu_qyZF8KJU3aQiCX9Cy00nijxZZSSTbZfx8tm_ZYGJiBeeedmQehD5S0lFD5Zd_Cfgb72DJCVUt4S5h6gzZUyb7hrBNv0YYwxpuOcXGB3uW8J4R0kpBzdMF63g1EdBt0-A7Z78JnnA-hPNY6YxMc3vo4xZ23ZsKwmmkxxceA44hDXGHCwZfkLY7P3kHjYqjtsMNPKZa4hVTDB8CuprV2VqieR9viyzLHhM0OQsnv0dlopgxXr_kS_b69ebj-2dzd__h1_e2usVyy0ijFpJOdM0IxYpUCkE5IIYFtpRnNIBlTYmDDyIEyy6QYhTOS9sYSyQdj-CX6dPKt5_1ZIBc9-2xhmkyAuGRN-55TpTjjVSpOUptizglG_ZT8bNJBU6KP0PVen6DrI3RNuK7Q69jH1w3Ldgb3b-gv5Sr4ehJA_XP1kHS2HoIF5xPYol30_9_wAuUulz0</recordid><startdate>20170526</startdate><enddate>20170526</enddate><creator>Chen, Jichao</creator><creator>Wang, Tianyu</creator><creator>Xu, Shengtao</creator><creator>Lin, Aijun</creator><creator>Yao, Hequan</creator><creator>Xie, Weijia</creator><creator>Zhu, Zheying</creator><creator>Xu, Jinyi</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170526</creationdate><title>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</title><author>Chen, Jichao ; Wang, Tianyu ; Xu, Shengtao ; Lin, Aijun ; Yao, Hequan ; Xie, Weijia ; Zhu, Zheying ; Xu, Jinyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antitumor activity</topic><topic>Apoptosis - drug effects</topic><topic>Berberine</topic><topic>Berberine Alkaloids - chemistry</topic><topic>Berberine Alkaloids - pharmacology</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Cell Cycle Checkpoints - drug effects</topic><topic>Hep G2 Cells</topic><topic>Heterografts</topic><topic>Humans</topic><topic>Hybrid compound</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Mice</topic><topic>Nitric oxide (NO) donor</topic><topic>Nitric Oxide - metabolism</topic><topic>Palmatine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jichao</creatorcontrib><creatorcontrib>Wang, Tianyu</creatorcontrib><creatorcontrib>Xu, Shengtao</creatorcontrib><creatorcontrib>Lin, Aijun</creatorcontrib><creatorcontrib>Yao, Hequan</creatorcontrib><creatorcontrib>Xie, Weijia</creatorcontrib><creatorcontrib>Zhu, Zheying</creatorcontrib><creatorcontrib>Xu, Jinyi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jichao</au><au>Wang, Tianyu</au><au>Xu, Shengtao</au><au>Lin, Aijun</au><au>Yao, Hequan</au><au>Xie, Weijia</au><au>Zhu, Zheying</au><au>Xu, Jinyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2017-05-26</date><risdate>2017</risdate><volume>132</volume><spage>173</spage><epage>183</epage><pages>173-183</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>A novel class of NO-donating protoberberine derivatives were synthesized and initially evaluated for their anti-hepatocellular carcinoma activities. Most of the compounds exhibited more potent activity against HepG2 cells than parent compounds berberine and palmatine. In particular, compound 15a exerted the strongest activity with an IC50 value of 1.36 μM. Moreover, most compounds released moderate levels of NO in vitro, and the antitumor activity of 15a in HepG2 cells was remarkably diminished by an NO scavenger. Interestingly, compound 15a displayed a broad-spectrum antitumor efficacy and possessed good selectivity between tumor cells (HepG2, SMMC-7721, HCT-116, HL-60) and normal liver LO-2 cells. The mechanism studies revealed that 15a blocked the G2 phase of the cell cycle and induced apoptosis of HepG2 cells by mitochondrial depolarization. Furthermore, 15a inhibited tumor growth in H22 liver cancer xenograft mouse model by 62.5% (w/w), which was significantly superior to parent compound palmatine (41.6%, w/w). Overall, the current study may provide a new approach for the discovery of novel antitumor agents. [Display omitted] •Eighteen novel NO-donating protoberberine derivatives were synthesized.•Most compounds showed significantly enhanced in vitro anti-proliferative activity.•15a exhibited good selectivity between tumor cells and normal liver LO-2 cells.•The antitumor activity of 15a in HepG2 cells was diminished by an NO scavenger.•15a effectively inhibited liver tumor growth in an in vivo mouse model.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28359045</pmid><doi>10.1016/j.ejmech.2017.03.027</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2017-05, Vol.132, p.173-183
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_1883177323
source Elsevier
subjects Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antitumor activity
Apoptosis - drug effects
Berberine
Berberine Alkaloids - chemistry
Berberine Alkaloids - pharmacology
Carcinoma, Hepatocellular - drug therapy
Cell Cycle Checkpoints - drug effects
Hep G2 Cells
Heterografts
Humans
Hybrid compound
Liver Neoplasms - drug therapy
Mice
Nitric oxide (NO) donor
Nitric Oxide - metabolism
Palmatine
title Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A36%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis%20and%20biological%20evaluation%20of%20novel%20nitric%20oxide-donating%20protoberberine%20derivatives%20as%20antitumor%20agents&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Chen,%20Jichao&rft.date=2017-05-26&rft.volume=132&rft.spage=173&rft.epage=183&rft.pages=173-183&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.03.027&rft_dat=%3Cproquest_cross%3E1883177323%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-7726d65da4720c77ee6d4646e2b6afa962274929f3e12c264f4da618ac0639aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1883177323&rft_id=info:pmid/28359045&rfr_iscdi=true